Switching from intravenous to subcutaneous infliximab biosimilar (Remsima®) in adult patients with inflammatory bowel disease: experience at an NHS trust
Dr. Ajay Verma, consultant gastroenterologist and physician, and Anusha Patel, regional homecare lead pharmacist and high cost medicines pharmacist, at Kettering General Hospital NHS Trust, share their experience of implementing a switch from intravenous (IV) to subcutaneous (SC) infliximab biosimilar for stable patients with inflammatory bowel disease (IBD).
Read the Guidelines in practice supplement (click here) to learn about:
- reasons for switching to SC infliximab biosimilar
- planning the switch—including identifying
- suitable patients and implementing the switch
- switch outcomes—patient response, efficacy and
- tolerability, and hospital outcomes
- addressing potential barriers to switching
- future plans.
To find out more about Switching from intravenous to subcutaneous infliximab:
Join Dr. Ajay Verma and Dr. Philip Smith on Thursday 21st January -16:05 to 16.45 GMT at BSG campus virtual industry session: Making the switch: Real-world experience of transitioning from intravenous (IV) to subcutaneous (SC) infliximab.
Prescribing information and adverse event reporting details can be found on the back pages of the supplement.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to
Celltrion Healthcare and its authorised commercialisation partners by calling +44 (0)1279 406759 (Diamond Pharma Services)
CTHC-UK-346 January 2021